Nussbaum, N
George, D J
Abernethy, A P
Dolan, C M
Oestreicher, N
Flanders, S
Dorff, T B
Article History
Received: 7 July 2015
Accepted: 4 August 2015
First Online: 2 February 2016
Competing interests
: DJG has received research support from Astellas, Exelixis, Genentech, GlaxoSmithKline, Cougar Biotechnology (now Janssen Oncology), Millennium, Novartis, Pfizer, Viamet, and Progenics, consultancy fees from Astellas, Aveo, Bayer, Dendreon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Novartis, Pfizer, Sanofi, Teva, Viamet, and Progenics, and honoraria from Dendreon and Sanofi. CMD is a paid consultant for Genentech, Iconic Therapeutics, Medivation, and Relypsa. NO was an employee of Medivation when the article was developed and owns stock in Medivation. SF is an employee of Astellas and holds stock in Johnson & Johnson. TBD has received research support from BMS, and has served as a consultant for Dendreon, Janssen, and Medivation, and has received honoraria from Astellas, Bayer, Pfizer, and Sanofi. The remaining authors declare no conflict of interest.